Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Wolfe Research Initiates Coverage On Celldex Therapeutics with Outperform Rating

Author: Benzinga Newsdesk | June 11, 2024 02:13pm
Wolfe Research analyst Andy Chen initiates coverage on Celldex Therapeutics (NASDAQ:CLDX) with a Outperform rating.

Posted In: CLDX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist